Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laina Feinstein

Internal Medicine Southfield, MI Medical Doctor

NPI 1467431031 CMS profile 292816

29829 Telegraph Rd, Suite 107, Southfield, MI 48034

Open in the dashboard

General payments

$8,451

511 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laina Feinstein of Southfield, MI is reported in the CMS Open Payments database as having received $8,451 across 511 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $541 28
2024 General $1,423 82
2023 General $1,445 82
2022 General $1,095 65
2021 General $1,502 90
2020 General $1,004 55
2019 General $1,441 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laina Feinstein
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Laina Feinstein were reported at $541. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Laina Feinstein Internal Medicine median Middle half National median
2019 $1,441 $159 $48–$570 $163
2020 $1,004 $119 $33–$402 $114
2021 $1,502 $135 $37–$521 $132
2022 $1,095 $141 $42–$496 $149
2023 $1,445 $149 $45–$519 $160
2024 $1,423 $154 $47–$537 $164
2025 $541 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $847 55 payments
  2. AbbVie, Inc. $805 50 payments
  3. Novo Nordisk Inc $741 46 payments
  4. GlaxoSmithKline, LLC. $491 32 payments
  5. Pfizer Inc. $455 31 payments
  6. Nestle HealthCare Nutrition Inc. $422 24 payments
  7. Merck Sharp & Dohme Corporation $421 26 payments
  8. Lilly USA, LLC $417 37 payments
  9. Novartis Pharmaceuticals Corporation $369 21 payments
  10. Amgen Inc. $341 20 payments
  11. Other $3,142 169 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,451 511 payments
Products named General payments · program years 2019–2025
  1. Ozempic $726 45 payments
  2. RYBELSUS $667 40 payments
  3. ZENPEP $543 31 payments
  4. VERQUVO $525 30 payments
  5. CREON $490 31 payments
  6. LINZESS $457 27 payments
  7. FARXIGA $398 27 payments
  8. TRELEGY ELLIPTA $361 23 payments
  9. Repatha $310 18 payments
  10. ENTRESTO $291 17 payments
  11. Other $7,477 473 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 222 drugs

Part D claims

15,030

Median for Internal Medicine: 777

Drug cost

$1,995,310

Median for Internal Medicine: $73,373

Branded share of claims

27.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 176 $186,181
Linzess Linaclotide Brand 248 $180,374
Farxiga Dapagliflozin Propanediol Brand 153 $135,029
Jardiance Empagliflozin Brand 117 $115,724
Mounjaro Tirzepatide Brand 71 $102,937
Humira Adalimumab Brand 14 $91,877
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 95 $82,159
Gemtesa Vibegron Brand 106 $76,460
Creon Lipase/Protease/Amylase Brand 86 $74,167
Tradjenta Linagliptin Brand 63 $67,800

The 10 drugs with the highest cost, of 222 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$539,422

Of which drugs: $1,789

Medicare patients

432

Average age 79

Services billed

13,656

276 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 43%
Ischemic heart disease 43%
Chronic kidney disease 31%
Heart failure 23%
Depression 22%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 35 35 $750
Injection, methylprednisolone acetate, 1 mg J1010 Office 53 4,480 $446
Injection, methylprednisolone acetate, 20 mg J1020 Office 24 76 $234
Injection, ceftriaxone sodium, per 250 mg J0696 Office 14 68 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
$153 — —
GEMTESA
$102 106 —
AIRSUPRA
$86 — —
ZENPEP
$82 18 —
Veozah
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

511 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record